REGULATORY

New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development

August 29, 2014

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Yoshihiro Abe, a new healthcare provider representative of the Central Social Insurance Medical Council (Chuikyo), offered a view on August 27 that the provisional pricing premium for new drug development is speeding up the development of unapproved drugs with medical…

To read the full story

Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014

REGULATORY

Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
December 24, 2025
Heparinoid, Allergy Drugs among OTC-Like Meds Up for Special Charge Rule
December 24, 2025
Japan Hands Out Orphan Designation to 11 Drugs
December 24, 2025
Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
Japan, Spain Move to Deepen Pharmaceutical Regulatory Cooperation
December 23, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…